Screener
Vera Therapeutics VERA Interest Expense
Interest Expense at other companies
Other financials
Where this comes from
Reported directly by Vera Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:InterestExpenseNonoperating.
The source filing: Vera Therapeutics’s 10-Q, filed May 7, 2026.
- Filed
- May 7, 2026, 4:33 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-212143
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Loss from operations | (125,132) | (57,194) |
| Other income (expense): | ||
| Interest income | 6,355 | 6,906 |
| Interest expense | (1,823) | (1,792) |
| Other (expense) income, net | (432) | 386 |
| Total other income, net | 4,100 | 5,500 |
| Net loss | $(121,032) | $(51,694) |
| Other comprehensive income: |
Item 1. Financial Statements
FAQ
- What is Vera Therapeutics's interest expense?
- Vera Therapeutics (VERA) reported interest expense of $1.82M in Q1 2026.
- How has Vera Therapeutics's interest expense changed year-over-year?
- Vera Therapeutics's interest expense increased by 1.7% year-over-year, from $1.79M to $1.82M.
- What is the long-term trend for Vera Therapeutics's interest expense?
- Over 4 years (2021 to 2025), Vera Therapeutics's interest expense has grown at a 340.5% compound annual growth rate (CAGR), from $20K to $7.53M.
- What does interest expense mean?
- Cost of borrowing — interest paid or accrued on bonds, bank loans, credit facilities, finance leases, and other debt obligations.
Ask your AI about Vera Therapeutics's interest expense.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude